Rademikibart Trial Reported Positive COPD Results
Connect Biopharma shared promising data from its Phase 2 clinical study of a potential new COPD treatment.
Updated on Sept. 30, 2026 in Asthma
Live Poll
Should developers prioritize new, specialized antibody treatments for chronic respiratory conditions like COPD?
Connect Biopharma has announced positive Phase 2 clinical trial results for its drug rademikibart in patients experiencing COPD exacerbations. The company now plans to consult with the FDA to initiate a Phase 3 registrational development program.
Why it matters
The study aims to address the significant unmet medical need for effective therapies following acute COPD exacerbations. Such treatments could potentially reduce the high burden of hospitalizations and emergency visits associated with the condition.
The Seabreeze STAT COPD study enrolled 159 participants, showing a 100% reduction in new hospitalizations and emergency visits through Week 4. Rademikibart achieved these results with a safety profile comparable to the placebo group.
The players
Connect Biopharma
This is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing new therapies for inflammatory diseases.
U.S. Food and Drug Administration
The FDA is a federal agency responsible for protecting public health by regulating the safety and efficacy of human drugs and biological products.
The details
Participants in the double-blind trial received a single subcutaneous dose of either rademikibart or a placebo to measure clinical outcomes within 28 days. The study results showed a 70 mL improvement in FEV1 over placebo, highlighting the drug's potential efficacy.
Timeline
September 30, 2026: Connect Biopharma released study results and held a conference call.
Week 4: The efficacy measurement period concluded for the study participants.
Week 8: The safety observation period for all study participants concluded.
The Big Picture
This development follows the standard regulatory path established by the FDA registrational development program process to advance new therapies from Phase 2 efficacy testing into large-scale pivotal clinical trials.
Patients suffering from COPD may eventually gain access to a new subcutaneous treatment designed to prevent severe exacerbations and hospital stays. The drug aims to reduce the estimated $6 billion in annual healthcare costs linked to emergency department returns.
The takeaway
This successful trial highlights the potential of biologics to mitigate the severity of COPD flare-ups. Future medical advances in this space will focus on sustaining these outcomes through larger Phase 3 investigations.
Further reading
Learn more about ongoing respiratory research on our Asthma page.
More information
View the official ClinicalTrials.gov study registration page for complete trial documentation.
Live Poll
Should developers prioritize new, specialized antibody treatments for chronic respiratory conditions like COPD?
